@stew80 I wrote: "Exercise reduced the risk of cancer recurrence or death by 28%. ADT vrs no ADT does not improve patient outlook by that much."

I meant ADT does not improve patient outlook compared to no ADT, by as much as the 28% improvement found in the CHALLENGE study I was discussing. I didn't mean to imply that ADT was not a first line treatment.

I was thinking about my specific case, which has been summed up by my radiation oncologist as "cT3b". He also describes me as "at least high risk" although he has no evidence that it has metastasized except to the seminal vesicles. He has a senior position at an NCI designated cancer facility, and when I asked how much of a benefit I can expect if I accept his prescription for 2 years of ADT, he said 20%.

I realize that the benefit of ADT varies according to the stage of cancer that is being treated. However I agree with those who say now that evidence such as the CHALLENGE trial exists, it is time for the doctors and patients to change their attitudes to the benefits of exercise, from the current "it can't hurt", or it seems like a "good idea", to something as valuable in cancer care as things like ADT or chemo, i.e. first line recommended treatment, with recommendations and supervision paid for by insurance.